J7170 HCPCS code: Injection, emicizumab-kxwh, 0.5 mg
J7170 is the HCPCS Level II code for injection, emicizumab-kxwh, 0.5 mg. In 2024 Medicare paid an average of $41.57 per service for J7170 across 4,084,546 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 1800 per day on outpatient hospital claims. Medicare volume rose 14% from 2022 to 2024 (3,577,793 to 4,084,546 services). In 2024, about 132 clinicians billed Medicare for J7170 for 391 beneficiaries; California, Pennsylvania, Illinois accounted for 56% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-01-01 |
| Last action effective | 2019-01-01 |
Who bills J7170 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 132 |
| Medicare beneficiaries | 391 |
| States with claims | 12 |
| Share of services in top 3 states (California, Pennsylvania, Illinois) | 56% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J7170, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 3,577,793 | 376 | $53.23 | $42.50 |
| 2023 | 4,181,267 | 412 | $51.75 | $41.24 |
| 2024 | 4,084,546 | 391 | $52.16 | $41.57 |
States with the most J7170 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 788,508 | $40.06 |
| Pennsylvania | 784,560 | $39.89 |
| Illinois | 209,060 | $40.29 |
| Michigan | 195,840 | $38.81 |
| Tennessee | 194,492 | $40.37 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 1800 | Prescribing Information |
| practitioner claims | 1800 | Prescribing Information |
Medicare policy articles for this code
- A56065: Billing and Coding: Guidance for Anti-Inhibitor Coagulant Complex (AICC) National Coverage Determination (NCD) 110.3 (Palmetto GBA (MAC - Part B))
- A56065: Billing and Coding: Guidance for Anti-Inhibitor Coagulant Complex (AICC) National Coverage Determination (NCD) 110.3 (Palmetto GBA (MAC - Part B))
Covered diagnoses (15 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| D66 | Hereditary factor VIII deficiency | 1 |
| D67 | Hereditary factor IX deficiency | 1 |
| D68.01 | Von Willebrand disease, type 1 | 1 |
| D68.020 | Von Willebrand disease, type 2A | 1 |
| D68.021 | Von Willebrand disease, type 2B | 1 |
| D68.022 | Von Willebrand disease, type 2M | 1 |
| D68.023 | Von Willebrand disease, type 2N | 1 |
| D68.03 | Von Willebrand disease, type 3 | 1 |
| D68.04 | Acquired von Willebrand disease | 1 |
| D68.09 | Other von Willebrand disease | 1 |
Showing 10 of 15. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J7170
- 2019-01-01: J7170 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J7170?
J7170 is the HCPCS Level II code for injection, emicizumab-kxwh, 0.5 mg. Short descriptor: "Inj., emicizumab-kxwh 0.5 mg".
How much does Medicare pay for J7170?
In 2024, the average Medicare payment was $41.57 per service (average allowed $52.16).
Does Medicare cover J7170?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J7170?
Medicare policy articles that cite J7170 list 15 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include D66 (Hereditary factor VIII deficiency), D67 (Hereditary factor IX deficiency), D68.01 (Von Willebrand disease, type 1). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J7170 can be billed per day?
1800 on outpatient hospital claims; 1800 on practitioner claims (NCCI medically unlikely edits).
Related J71 codes
- J7100 — Infusion, dextran 40, 500 ml
- J7110 — Infusion, dextran 75, 500 ml
- J7120 — Ringers lactate infusion, up to 1000 cc
- J7121 — 5% dextrose in lactated ringers infusion, up to 1000 cc
- J7131 — Hypertonic saline solution, 1 ml
- J7165 — Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
- J7168 — Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity
- J7169 — Injection, coagulation factor xa (recombinant), inactivated-zhzo (andexxa), 10 mg
- J7171 — Injection, adamts13, recombinant-krhn, 10 iu
- J7172 — Injection, marstacimab-hncq, 0.5 mg
- J7173 — Injection, concizumab-mtci, 0.5 mg
- J7174 — Injection, fitusiran, 0.04 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J7170
- Watch J7170 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7170
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.